Renaissance Technologies’s Utah Medical Products UTMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$11.4M Sell
184,114
-9,500
-5% -$598K 0.02% 909
2025
Q4
$10.8M Sell
193,614
-7,300
-4% -$423K 0.02% 875
2025
Q3
$12.7M Sell
200,914
-12,400
-6% -$734K 0.02% 972
2025
Q2
$12.1M Sell
213,314
-4,400
-2% -$239K 0.02% 954
2025
Q1
$12.2M Sell
217,714
-3,796
-2% -$227K 0.02% 898
2024
Q4
$13.6M Sell
221,510
-9,104
-4% -$589K 0.02% 828
2024
Q3
$15.4M Buy
230,614
+3,500
+2% +$238K 0.02% 807
2024
Q2
$15.2M Sell
227,114
-5,400
-2% -$368K 0.03% 718
2024
Q1
$16.5M Buy
232,514
+27,900
+14% +$2.09M 0.03% 726
2023
Q4
$17.2M Sell
204,614
-900
-0.4% -$74.6K 0.03% 671
2023
Q3
$17.7M Buy
205,514
+2,122
+1% +$196K 0.03% 627
2023
Q2
$19M Sell
203,392
-3,322
-2% -$313K 0.03% 703
2023
Q1
$19.6M Sell
206,714
-3,900
-2% -$358K 0.03% 726
2022
Q4
$21.2M Sell
210,614
-5,900
-3% -$539K 0.03% 684
2022
Q3
$18.5M Sell
216,514
-10,856
-5% -$958K 0.03% 720
2022
Q2
$19.5M Buy
227,370
+3,656
+2% +$312K 0.02% 742
2022
Q1
$20.1M Buy
223,714
+800
+0.4% +$73.6K 0.02% 751
2021
Q4
$22.3M Sell
222,914
-7,121
-3% -$727K 0.03% 652
2021
Q3
$21.4M Sell
230,035
-13,879
-6% -$1.23M 0.03% 650
2021
Q2
$20.7M Sell
243,914
-3,000
-1% -$260K 0.03% 741
2021
Q1
$21.4M Sell
246,914
-823
-0.3% -$72.4K 0.03% 732
2020
Q4
$20.9M Buy
247,737
+6,923
+3% +$590K 0.02% 732
2020
Q3
$19.2M Buy
240,814
+7,100
+3% +$589K 0.02% 760
2020
Q2
$20.7M Buy
233,714
+2,200
+1% +$197K 0.02% 797
2020
Q1
$21.8M Sell
231,514
-2,700
-1% -$251K 0.02% 720
2019
Q4
$25.3M Sell
234,214
-3,300
-1% -$334K 0.02% 881
2019
Q3
$22.8M Sell
237,514
-11,000
-4% -$1.02M 0.02% 889
2019
Q2
$23.8M Buy
248,514
+10,266
+4% +$864K 0.02% 870
2019
Q1
$21M Sell
238,248
-966
-0.4% -$84.9K 0.02% 942
2018
Q4
$19.9M Sell
239,214
-11,369
-5% -$1M 0.02% 888
2018
Q3
$23.6M Buy
250,583
+24,283
+11% +$2.32M 0.02% 830
2018
Q2
$24.9M Buy
226,300
+7,378
+3% +$770K 0.03% 794
2018
Q1
$21.6M Buy
218,922
+6,722
+3% +$600K 0.02% 895
2017
Q4
$17.3M Buy
212,200
+18,900
+10% +$1.48M 0.02% 1045
2017
Q3
$14.2M Buy
193,300
+26,755
+16% +$1.92M 0.02% 1107
2017
Q2
$12.1M Buy
166,545
+21,845
+15% +$1.44M 0.02% 1152
2017
Q1
$9.02M Buy
144,700
+7,700
+6% +$485K 0.01% 1309
2016
Q4
$9.97M Buy
137,000
+2,000
+1% +$130K 0.02% 1230
2016
Q3
$8.07M Buy
135,000
+4,500
+3% +$286K 0.01% 1289
2016
Q2
$8.22M Buy
130,500
+6,769
+5% +$437K 0.02% 1267
2016
Q1
$7.74M Buy
123,731
+14,731
+14% +$869K 0.01% 1307
2015
Q4
$6.38M Buy
109,000
+14,200
+15% +$805K 0.01% 1302
2015
Q3
$5.11M Buy
94,800
+2,400
+3% +$131K 0.01% 1383
2015
Q2
$5.51M Buy
92,400
+2,400
+3% +$135K 0.01% 1377
2015
Q1
$5.39M Buy
90,000
+1,300
+1% +$76.4K 0.01% 1312
2014
Q4
$5.33M Buy
88,700
+1,000
+1% +$55.4K 0.01% 1231
2014
Q3
$4.28M Buy
87,700
+400
+0.5% +$20.3K 0.01% 1248
2014
Q2
$4.49M Buy
87,300
+7,000
+9% +$359K 0.01% 1279
2014
Q1
$4.64M Buy
80,300
+4,900
+6% +$267K 0.01% 1297
2013
Q4
$4.31M Buy
75,400
+7,300
+11% +$400K 0.01% 1276
2013
Q3
$4.05M Buy
68,100
+13,400
+24% +$731K 0.01% 1284
2013
Q2
$2.97M Buy
+54,700
New +$2.58M 0.01% 1372

Other funds holding UTMD

Renaissance Technologies's UTMD Position: Q1 2026 in Review

Renaissance Technologies reduced its Utah Medical Products (UTMD) stake by 4.9% in Q1 2026, selling an estimated $598K and leaving 184,114 shares worth $11.4M. The position accounts for 0.02% of the portfolio, ranked #909.

Renaissance Technologies first reported a position in UTMD in Q2 2013 and has held it in 52 quarters since. The position peaked at $25.3M in Q4 2019. 119 funds tracked by Wall St. Rank hold UTMD as of Q1 2026.

  • Renaissance Technologies held 184,114 shares of Utah Medical Products worth $11.4M as of Q1 2026.
  • Renaissance Technologies sold 9,500 Utah Medical Products shares in Q1 2026, an estimated $598K.
  • Utah Medical Products made up 0.02% of Renaissance Technologies's portfolio in Q1 2026, its #909 holding.
  • Renaissance Technologies first reported a position in Utah Medical Products in Q2 2013 and has held it in 52 quarters since.
  • Renaissance Technologies's Utah Medical Products position peaked at $25.3M in Q4 2019.
  • 119 funds tracked by Wall St. Rank held Utah Medical Products as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.